ClinicalTrials.gg
RecruitingNCT07750067Updated Aug 10, 2026

Tunlametinib in Combination With Pucotenlimab and Hydroxychloroquine in NRAS Mutant Melanoma

A Phase 2 interventional study of Tunlametinib and Pucotenlimab in Melanoma Metastatic and NRAS Mutation, sponsored by Sun Yat-sen University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-10.

Sponsored by Sun Yat-sen University · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Apr 2026, registered Aug 2026).
  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
37
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 203 studies in Melanoma with a site in China — 83 open to participants now, 96 under way, 5 of them phase 3. Melanoma · China.

Planned enrollment
124th of 189
37 · median 50
Started
2026
with 19 others
Phase 2
75 of 203
30 open now
Primary completion
2030-07
later than 92 of 95 live
Registered
199th of 203
by date
Lead sponsor
7 of 203
Sun Yat-sen University

Among the 203 studies in Melanoma with a site in China, this one is the 124th largest by planned enrollment of the 189 interventional ones that give a count, is one of 20 that started in 2026, is one of 75 in phase 2, reaches primary completion later than 92 of the 95 other live ones, and was the 199th registered.

Melanoma

3,373 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

83 of the 203 studies in Melanoma with a site in China are open now. Recruiting first, the newest first:

77 more — sign in →

All 83 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 203 studies in Melanoma with a site in China, or all of them as a file.
02

Study summary

This study evaluates the combination of the autophagy inhibitor hydroxychloroquine (HCQ), the MEK inhibitor tunlametinib, and the anti-PD-1 antibody pucotenlimab in patients with locally advanced or metastatic melanoma. The primary objectives are to assess the objective response rate (ORR) and progression-free survival (PFS). Secondary objectives include evaluating adverse events (type, severity, and incidence), duration of response (DOR), disease control rate (DCR), and overall survival (OS), as well as exploring the molecular mechanisms by which autophagy modulation enhances immunogenicity in mutant melanoma. Further exploratory analyses will examine the mechanisms by which autophagy inhibition enhances tumor sensitivity to PD-1 blockade, thereby establishing experimental and theoretical grounds for refining future clinical approaches.

03

Conditions studied

  • Melanoma Metastatic
  • NRAS Mutation

Browse trials for

Keywords

  • Tunlametinib
  • Pucotenlimab
  • Hydroxychloroquine
  • NRAS mutation
  • melanoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years of age, both genders.
  • Subjects with unresectable or melanoma (Stage III/IV) confirmed by histology or cytology
  • The mutated NRAS genes were confirmed by sequencing.
  • Prior systemic antineoplastic therapy is allowed. All acute toxic effects of prior antitumor therapy must have resolved to grade 1 or lower before the start of the study drug, with the exception of alopecia (grade 1 or 2 permitted), neurotoxicity (grade 1 or 2 permitted), or bone marrow parameters (grade 1, 2, or 3 permitted).
  • , 0-2.
  • The life expectance should be at least 12 months.
  • Eligible subjects had not received chemotherapy for locally advanced or metastatic disease and had at least one according to the (RECIST 1.1 criteria).
  • To ensure eligibility, the following criteria must be met regarding major organ and bone marrow functions: Adequate bone marrow function: (ANC)≥ 1.5\^109/L, count (PLT)≥ 100\^109/L, and level (HB)≥ 9 g/dL (no transfusion received within 14 days). Serum total (TBIL) must be ≤ 1.5 times the (ULN). (AST) and alanine aminotransferase (ALT) ≤2.5 times the upper limits of normal, serum creatinine ≤1.5, and had to be greater than 50 mL/min. Creatinine clearance, as an estimate of (eGFR), was calculated according to the Cockcroft and Gault (C\&G) equation (26): (140 - age [years] × weight [kg] × 0.85 for male)/ 72*serum creatinine (μmol/L). The (INR) and activated partial thromboplastin time (aPTT) were a maximum of 1.5 fold the upper limit of normal (This provision applies only to Subjects not receiving anticoagulant therapy; for Subjects receiving anticoagulant therapy, anticoagulation should be within the therapeutic range.). Urine protein ≤ 1+; if urine protein > 1+, a 24-hour urine collection for protein quantification is required, and the total protein must be ≤ 1 g; FT3, FT4, and TSH levels should be normal, or any abnormalities should be clinically insignificant; lactate dehydrogenase (LDH) ≤ 2 × upper limit of normal (ULN).
  • A urine pregnancy test must be negative within 7 days before enrollment for women of .Male and female Subjects of reproductive/childbearing potential must use highly effective (e.g., oral contraceptives, IUDs, abstinence, or barrier plus spermicide) during the entire trial and for 12 months after treatment ends.
  • The subject voluntarily joins the study, has good compliance, and is cooperative with follow-up evaluations.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have previously received antibody, anti-PD-L1/PD-L2 antibody therapy, and/or VEGFR TKI therapy.
  • Subjects currently receiving systemic anti-tumor therapy.
  • Subjects who have participated in or are currently participating in other drug/therapy clinical trials within 4 weeks prior to enrollment (calculated from the date of the last dose of the previous trial).
  • Subjects who have undergone major surgery within 4 weeks prior to enrollment, or have not recovered from surgical side effects, or have received within 4 weeks prior to enrollment.
  • Subjects with a history of other invasive within the previous 5 years other than nonmelanoma skin cancer were excluded, except for curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, early-stage prostate cancer, and cervical carcinoma in situ.
  • Subjects who have received hematopoietic growth factors, such as granulocyte colony-stimulating factor (G-CSF), erythropoietin, etc., within 1 week prior to enrollment.
  • Subjects with positive test results for antibody or Treponema pallidum antibody (based on test results from a Grade A tertiary hospital, including the study center).
  • Subjects with active or who have not received antiviral therapy: if HBsAg or HBcAb is positive, HBVDNA should be tested (with results above the at the research center); if HCV antibody is positive, HCVRNA should be tested (with results above the upper limit of normal range at the research center).
  • Subjects with known allergy to humanized anti-PD-1 monoclonal antibody drugs and their components; known allergy to MEK inhibitors (e.g., Tunlametinib) and any of their ; known allergy to autophagy inhibitors (e.g., hydroxychloroquine) and any of their excipients.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
37 participants (estimated)

Study arms

  • Experimental
    Tunlametinib + Pucotenlimab + Hydroxychloroquine

    PD-1 antibody (pucotenlimab): Administered via intravenous infusion over at least 60 minutes, using an in-line filter (0.2-5 μm). The drug is diluted with normal saline prior to infusion. One treatment cycle is defined as 3 weeks (21 days). Tunlametinib (3 mg/tablet): The recommended dose is 12 mg (4 tablets) orally twice daily (approximately every 12 hours), with or without food. Capsules must not be chewed, dissolved, or opened. If a dose is missed, it may be taken up to 8 hours before the next scheduled dose; if the missed dose is discovered within 8 hours of the next dose, it should be skipped. Hydroxychloroquine (0.1 g/tablet): Administered orally at 2 tablets (0.2 g) twice daily, to be taken with meals or milk. Each treatment course consists of 4 consecutive weeks of administration, i.e., 30 days per course. Treatment discontinuation criteria: Patients were permitted to continue treatment until disease progression or development of unacceptable toxicity.

    Drug: Tunlametinib · Drug: Pucotenlimab · Drug: Hydroxychloroquine (HC)

Interventions

  • Tunlametinib (3 mg/tablet): The recommended dose is 12 mg (4 tablets) orally twice daily (approximately every 12 hours), with or without food. Capsules must not be chewed, dissolved, or opened. If a dose is missed, it may be taken up to 8 hours before the next scheduled dose; if the missed dose is discovered within 8 hours of the next dose, it should be skipped.

  • PD-1 antibody (pucotenlimab): Administered via intravenous infusion over at least 60 minutes, using an in-line filter (0.2-5 μm). The drug is diluted with normal saline prior to infusion. One treatment cycle is defined as 3 weeks (21 days).

  • Hydroxychloroquine (0.1 g/tablet): Administered orally at 2 tablets (0.2 g) twice daily, to be taken with meals or milk. Each treatment course consists of 4 consecutive weeks of administration, i.e., 30 days per course.

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Defined as the percentage of subjects achieving complete response (CR) or partial response (PR) as assessed by RECIST 1.1.

    Time frame: up to 180 days

  2. Progression Free Survival (PFS)

    Defined as the time from randomization to the date of first documentation of from date of randomization until the date of first documented progression or date of death from any cause, whichever came first.

    Time frame: up to 180 days

Secondary outcomes

  1. Disease Control Rate (DCR)

    DCR was defined as the proportion of CR+PR+SD subjects to total subjects

    Time frame: up to 180 days

  2. Duration of Response (DoR)

    DoR was defined as the time from when response (CR or PR) was first documented to first documented disease progression or death.

    Time frame: up to 180 days

  3. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0

    The safety profile will be characterized by reporting the number and percentage of participants (with 95% Clopper-Pearson confidence intervals) for the following endpoints: overall TEAEs, Grade ≥3 TEAEs, serious adverse events (SAEs), treatment-related AEs, AEs leading to permanent drug discontinuation, and AEs leading to dose modification. All AEs will be graded per CTCAE v4.0, and causality will be determined by the investigator.

    Time frame: 30 days (average of 3 months).

Other outcomes

  1. Integrated mechanistic biomarkers of autophagy-mediated neoepitope presentation and T-cell-dependent sensitization to PD-1 blockade.

    To investigate the mechanisms by which induced autophagy enhances immunogenicity and sensitises melanoma to PD-1-targeted therapy, we will conduct a correlative biomarker analysis using serial blood and available tumor samples. A panel of predefined markers related to autophagic activity, antigen presentation, and T-cell effector function will be assessed by standard laboratory techniques. Changes in these biomarker levels from baseline will be correlated with clinical outcomes (response, progression-free survival) and summarized using descriptive statistics (mean, standard deviation, median, range) and non-parametric correlation tests as appropriate. Detailed assay protocols and specific biomarker identities are not disclosed to preserve confidential information.

    Time frame: up to 720 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Jul 2030, 51 months after the start.

Of 278 non-industry phase 2 interventional studies under Melanoma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 94. This study's planned 51 months is below that.

Counting every sponsor, half of 384 studies reached it within 53 months; a quarter within 32 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2026
First posted
Aug 6, 2026
StartActual
Apr 1, 2026
Primary completionEst.
Jul 28, 2030
CompletionEst.
Jul 28, 2030
Last update
Aug 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07750067
Responsible party
Rongcheng Zhang (M.D., Sun Yat-sen University) — Principal investigator
First posted
Aug 6, 2026
Start date
Apr 1, 2026
Primary completion
Jul 28, 2030 (estimated)
Completion
Jul 28, 2030 (estimated)
Last update
Aug 10, 2026

Study contacts

Rong cheng Zhang MD, PhD
Contact
zhangrc@sysucc.org.cn
+86 19898802339 ext. +86 020-873439
Dandan Li MD, PhD
Contact
lidd@sysucc.org.cn
+86 13570573356

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tunlametinib · Pucotenlimab

Start the discussion